DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 7,915,283 B2 Wang Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 7,915,283 B2 Wang Et Al USOO7915283B2 (12) United States Patent (10) Patent No.: US 7,915,283 B2 Wang et al. (45) Date of Patent: *Mar. 29, 2011 (54) INDOLE, AZAINDOLE AND RELATED W W g ? 2. 4. 12: HETEROCYCLIC 4-ALKENYL PPERDINE WO WO 98.28292 7, 1998 AMIDES WO WOO2.04440 1, 2002 WO WO O2/O62423 8, 2002 (75) Inventors: Tao Wang, Farmington, CT (US); John F. Kadow, Wallingford, CT (US); OTHER PUBLICATIONS Nhel R St. Ret M. Font, et al., “Indoles and Pyridazino4,5-b]Indoles as Non (U ); ap. un Yeung, a. 1SOn, nucleoside Analog Inhibitors of HIV-1 Reverse Transcriptase.” Eur, (US). Zhongxing Zhang, Madison, CT J. Med. Chem., 30, pp.963-971, 1995. (US); Zhiwei Yin, Glastonbury, CT D.L. Romero, et al., J. Med. Chem., 36, pp. 1505-1508, 1993. (US); Zhilei Qui, Parsippany, NJ (US); S.D. Young, et al., “2-Heterocyclic indole-3-Sulfones as Inhibitors of Daniel H. Deon, Candiac (CA); Clint A. HIV-1 Reverse Transcriptase.” Bioorganic & Medicinal Chemistry James, Laprairie (CA); Edward H. Letters, 5(5), pp. 491–496, 1995. Ruediger, Greenfield Park (CA); Carol MJ . Genin, et al., “Synthesis and Bioactivity of Novel Bachand, Candiac (CA) Bis(Heteroaryl)Piperazine (BHAP) Reverse Transcriptase Inhibi s tors: Structure-Activity Relationships and Increased Metabolic Sta (73) Assignee: Bristol-Myers Squibb Company, by Nesbstituted Pyridine Analogs,” J. Med. Chem, 39, pp. Princeton, NJ (US) R. Silvestri, et al., Antiviral Chemistry & Chemotherapy, 9, pp. 139-148, 1998. (*) Notice: Subject to any disclaimer, the term of this A. Fredenhagen, et al., "Semicochiliodinol A and B: Inhibitors of patent is extended or adjusted under 35 HIV-1 Protease and EGF-RProtein Tyrosine Kinase Related to Aster U.S.C. 154(b) by 532 days. riquinones Produced by the Fungus Chrysosporium merdarium.” This patent is Subject to a terminal dis- Journal of Antibiotics, 50(5), pp. 395-401, 1997. claimer M. Kato, et al., “New 5-HT (Serotonin-3) Receptor Antagonists. IV. Synthesis and Structure-Activity Relationships of Azabicycloalkaneacetamide Derivatives.” Chem. Pharm. Bull. (21) Appl. No.: 12/015,767 43(8), pp. 1351-1357, 1995. V. Levacher, et al., "Broadening in the Scope of NADH Models by (22) Filed: Jan. 17, 2008 Using Chiral and Non-Chiral Pyrrolo 2,3-bPyridine Derivatives.” Tetrahedron, 47(3), pp. 429-440, 1991. (65) Prior Publication Data US 2008/O188481 A1 Aug. 7, 2008 * cited by examiner Related U.S. Application Data Primary Examiner — Bernard Dentz (60) Division of application No. 10/762,108, filed on Jan. (74) Attorney, Agent, or Firm — John F. Levis 21, 2004, now Pat. No. 7,348,337, which is a continuation-in-part of application No. 107425,370, (57) ABSTRACT filed on Apr. 29, 2003, now abandoned. (60) Provisional application No. 60/383,509, filed on May This invention provides compounds having drug and bio 28, 2002 affecting properties, their pharmaceutical compositions and s method of use. In particular, the invention is concerned with (51) Int. Cl. new piperidine 4-alkenyl derivatives that possess unique anti A6 IK3 L/454 (2006.01) viral activity. More particularly, the present invention relates A6 IK3 L/4545 (2006.01) to compounds useful for the treatment of HIV and AIDS. The (52) U.S. Cl. ........................................ 514/300: 514/323 COmpoundSpounds ofOf ththe 1nVent1On forOr the general FormulaFormula: I (58) Field of Classification Search .................. 514/300, 514/323 (I) See application file for complete search history. Zn W (56) References Cited U.S. PATENT DOCUMENTS wherein: 5,023,265 A 6/1991 Scherlocket al. Z is 5,124,327 A 6, 1992 Greenlee et al. 5,424,329 A 6, 1995 Boschelli et al. 6,469,006 B1 10/2002 Blair et al. O 6,476,034 B2 11/2002 Wang et al. 6,573,262 B2 6, 2003 Wallace et al. 7,348,337 B2 * 3/2008 Wang et al. ................... 514,300 Q FOREIGN PATENT DOCUMENTS EP O530907 A1 3, 1993 WO WO 93.01181 1, 1993 WO WO95/04742 2, 1995 Q is selected from the group consisting of: US 7,915,283 B2 Page 2 -continued —W– is R7 Riis P R16 R15 21 NA N R22 R19 R20 R21 18 Claims, No Drawings US 7,915,283 B2 1. 2 INDOLE, AZAINDOLE AND RELATED Ren et al: (Ref. 6-14)). Therefore, novel anti-HIV agents HETEROCYCLIC 4-ALKENYL PPERDINE exhibiting distinct resistance patterns, and favorable pharma AMIDES cokinetic as well as safety profiles are needed to provide more treatment options. CROSS REFERENCE TO RELATED Currently marketed HIV-1 drugs are dominated by either APPLICATIONS nucleoside reverse transcriptase inhibitors or peptidomimetic protease inhibitors. Non-nucleoside reverse transcriptase This is a Divisional application of U.S. application Ser. No. inhibitors (NNRTIs) have recently gained an increasingly 10 important role in the therapy of HIV infections (Pedersen & 10/762,108 filed Jan. 21, 2004, now allowed, which is a Pedersen, Ref 15). At least 30 different classes of NNRTI Continuation in Part application of U.S. Non-Provisional have been described in the literature (De Clercq Ref. 16) and application Ser. No. 10/425,370 filed Apr. 29, 2003, now several NNRTIs have been evaluated in clinical trials. Dipy abandoned, which claims the benefit of U.S. Provisional ridodiazepinone (nevirapine), benzoxazinone (efavirenz) and Application Ser. No. 60/383,509 filed May 28, 2002. 15 bis(heteroaryl)piperazine derivatives (delavirdine) have been approved for clinical use. However, the major drawback to the FIELD OF THE INVENTION development and application of NNRTIs is the propensity for rapid emergence of drug resistant strains, both in tissue cell This invention provides compounds having drug and bio culture and in treated individuals, particularly those subject to affecting properties, their pharmaceutical compositions and monotherapy. As a consequence, there is considerable inter method of use. In particular, the invention is concerned with est in the identification of NNRTIs less prone to the develop new piperidine 4-alkenyl derivatives that possess unique anti ment of resistance (Pedersen & Pedersen, Ref 15). A recent viral activity. More particularly, the present invention relates overview of non-nucleoside reverse transcriptase inhibitors: to compounds useful for the treatment of HIV and AIDS. perspectives on novel therapeutic compounds and strategies 25 for the treatment of HIV infection. has appeared (Buckheit, reference 99). A review covering both NRTI and NNRTIs has BACKGROUND ART appeared (De clercq, reference 100). An overview of the current state of the HIV drugs has been published (De clercq, HIV-1 (human immunodeficiency virus-1) infection 30 reference 101) remains a major medical problem, with an estimated 42 mil Several indole derivatives including indole-3-sulfones, lion people infected worldwide at the end of 2002. The num piperazino indoles, pyrazino indoles, and 5H-indolo 3.2-b ber of cases of HIV and AIDS (acquired immunodeficiency 1.5benzothiazepine derivatives have been reported as syndrome) has risen rapidly. In 2002, -5.0 million new infec HIV-1 reverse transciptase inhibitors (Greenlee et al. Ref. 1; tions were reported, and 3.1 million people died from AIDS. 35 Williams etal, Ref.2: Romero etal, Ref.3; Font etal, Ref. 17: Currently available drugs for the treatment of HIV include Romero et al. Ref. 18; Young et al. Ref. 19: Genin et al. Ref. nine nucleoside reverse transcriptase (RT) inhibitors or 20: Silvestri et al. Ref. 21). Indole 2-carboxamides have also approved single pill combinations (Zidovudine or AZT (or been described as inhibitors of cell adhesion and HIV infec RetrovirR), didanosine (or Videx(R), stavudine (or Zerit(R), tion (Boschellietal, U.S. Pat. No. 5,424,329, Ref. 4). 3-sub lamivudine (or 3TC or Epivir R), Zalcitabine (or DDC or 40 HividR), abacavir succinate (or ZiagenR), Tenofovir diso stituted indole natural products (Semicochliodinol A and B, proxil fumarate salt (or Viread(R), Combivir R (contains didemethylasterriquinone and isocochliodinol) were dis -3TC plus AZT), Trizivir R (contains abacavir, lamivudine, closed as inhibitors of HIV-1 protease (Fredenhagen et al. and Zidovudine); three non-nucleoside reverse transcriptase Ref.22). inhibitors: nevirapine (or Viramune(R), delavirdine (or 45 Structurally related aza-indole amide derivatives have been Rescriptor(R) and efavirenz (or SustivaR), and seven pepti disclosed previously (Kato et al. Ref.23; Levacher et al. Ref. domimetic protease inhibitors or approved formulations: 24: Dompe Spa, WO-09504742, Ref. 5(a); SmithKline Bee saquinavir, indinavir, ritonavir, nelfinavir, amprenavir, lopi cham PLC, WO-0961 1929, Ref. 5(b); Schering Corp., U.S. navir, and Kaletra R (lopinavir and Ritonavir). Each of these Pat. No. 5,023,265, Ref. 5(c)). However, these structures drugs can only transiently restrain viral replication if used 50 differ from those claimed herein in that they are aza-indole alone. However, when used in combination, these drugs have mono-amide rather than unsymmetrical aza-indole piperi a profound effect on viremia and disease progression. In fact, dine 4-alenyl derivatives, and there is no mention of the use of significant reductions in death rates among AIDS patients these compounds for treating viral infections, particularly have been recently documented as a consequence of the wide HIV. Indole and azaindole piperazine containing derivatives spread application of combination therapy. However, despite 55 these impressive results, 30 to 50% of patients ultimately fail have been disclosed in three different PCT and issued U.S. combination drug therapies. Insufficient drug potency, non patent applications (Reference 93-95, 106) Those com compliance, restricted tissue penetration and drug-specific pounds describe oxo acetyl Substituted piperazine amides. limitations within certain cell types (e.g. most nucleoside None of these applications discloses piperidine alkenyl com analogs cannot be phosphorylated in resting cells) may 60 pounds such as described in this invention. The selection of account for the incomplete Suppression of sensitive viruses.
Load more

Recommended publications
  • Arylsulfonylmethyl Isocyanides: a Novel Paradigm in Organic Synthesis
    RSC Advances This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication. Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. This Accepted Manuscript will be replaced by the edited, formatted and paginated article as soon as this is available. You can find more information about Accepted Manuscripts in the Information for Authors. Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains. www.rsc.org/advances Page 1 of 22 RSC Advances Arylsulfonylmethyl isocyanides: α-acidity in the structure of isocyanides Tanpreet Kaur, Preeti Wadhwa and Anuj Sharma* *Department of Chemistry, Indian Institute of Technology, Roorkee-247667, India (Phone: +91-1332-284751; e-mail: [email protected] ) Abstract: p-Tosylmethyl isocyanide (TosMIC), an α-acidic isocyanide has emerged as a privileged reagent to access biologically relevant scaffolds. The present review highlights the significant advancements of TosMIC in the construction of fused heterocycles viz. pyrroles, benzimidazoles, imidazopyridines, quinolones, quinolines and some natural products like (-)-Ushikulide A, Variolin B, Porphobilinogen and mansouramycin B. The review article encompasses literature from the period starting from 2010 onwards and covers novel synthetic methodologies involving TosMIC.
    [Show full text]
  • Recent Advances in the Synthesis of Oxazole-Based Molecules Via Van Leusen Oxazole Synthesis
    molecules Review Recent Advances in the Synthesis of Oxazole-Based Molecules via van Leusen Oxazole Synthesis Xunan Zheng 1,2, Wei Liu 3,* and Dawei Zhang 1,* 1 College of Chemistry, Jilin University, Changchun 130012, China; [email protected] 2 College of Plant Science, Jilin University, Changchun 130062, China 3 Department of Pesticide Science, Plant Protection College, Shenyang Agricultural University, Shenyang 110866, China * Correspondence: [email protected] (W.L.); [email protected] (D.Z.); Tel.: +86-188-1775-2588 (W.L.); +86-431-8783-6471 (D.Z.) Academic Editors: Anna Carbone and Fabio Bertozzi Received: 2 March 2020; Accepted: 23 March 2020; Published: 31 March 2020 Abstract: Oxazole compounds, including one nitrogen atom and one oxygen atom in a five-membered heterocyclic ring, are present in various biological activities. Due to binding with a widespread spectrum of receptors and enzymes easily in biological systems through various non-covalent interactions, oxazole-based molecules are becoming a kind of significant heterocyclic nucleus, which have received attention from researchers globally, leading them to synthesize diverse oxazole derivatives. The van Leusen reaction, based on tosylmethylisocyanides (TosMICs), is one of the most appropriate strategies to prepare oxazole-based medicinal compounds. In this review, we summarize the recent advances of the synthesis of oxazole-containing molecules utilizing the van Leusen oxazole synthesis from 1972, aiming to look for potential oxazole-based medicinal compounds, which are valuable information for drug discovery and synthesis. Keywords: van Leusen; TosMICs; oxazole; synthesis 1. Introduction The oxazole ring, with one nitrogen atom and one oxygen atom, which are widely displayed in natural products and synthetic molecules, is known as a prime skeleton for drug discovery.
    [Show full text]
  • An Investigation of Imidazole and Oxazole Syntheses Using Aryl-Substituted Tosmic Reagents1
    1516 J. Org. Chem. 2000, 65, 1516-1524 An Investigation of Imidazole and Oxazole Syntheses Using Aryl-Substituted TosMIC Reagents1 Joseph Sisko,*,† Andrew J. Kassick,‡ Mark Mellinger,† John J. Filan,† Andrew Allen,§ and Mark A. Olsen§ SmithKline Beecham Pharmaceuticals, Synthetic Chemistry Department and Analytical Sciences Department, P.O. Box 1539, King of Prussia, Pennsylvania 19406 Received November 16, 1999 This article describes efficient and mild protocols for preparing polysubstituted imidazoles in a single pot from aryl-substituted tosylmethyl isocyanide (TosMIC) reagents and imines generated in situ. Traditional imine-forming reactions employing virtually any aldehyde and amine followed by addition of the TosMIC reagent delivers 1,4,5-trisubstituted imidazoles with predictable regiochemistry. Employing chiral amines and aldehydes, particularly those derived from R-amino acids, affords imidazoles with asymmetric centers appended to N-1 or C-5 with excellent retention of chiral purity. 1,4-Disubstituted imidazoles are also readily prepared by a simple variant of the above procedure. Selecting glyoxylic acid as the aldehyde component of this procedure leads to intermediates such as 48, which readily undergo decarboxylation and elimination of the tosyl moiety to deliver 1,4-disubstituted imidazoles in high yields. Alternatively, using NH4OH as the amine component in conjunction with a variety of aldehydes delivers 4,5-disubstituted imidazoles in moderate to good yields in a single pot while avoiding the need for protecting groups. Finally, the facile preparation of mono- and disubstituted oxazoles from these TosMIC reagents and aldehydes is described. Introduction Scheme 1 Imidazoles are a common component of a large number of natural products and pharmacologically active mol- ecules.2 The prevalence and importance of this component makes methods which facilitate their preparation highly valuable.
    [Show full text]
  • Cascade Synthesis of 2,4-Disulfonylpyrroles by the Sulfonylation/[2 + 3]-Cycloaddition Reactions of Gem-Dibromoalkenes with Aryl
    RSC Advances PAPER View Article Online View Journal | View Issue Cascade synthesis of 2,4-disulfonylpyrroles by the sulfonylation/[2 + 3]-cycloaddition reactions of Cite this: RSC Adv.,2021,11,13292 gem-dibromoalkenes with arylsulfonyl methyl isocyanides† Parvin Salehi, Zahra Tanbakouchian, Noushin Farajinia-Lehi and Morteza Shiri * An efficient cascade reaction involving sulfonylation and [2 + 3]-cycloaddition reactions of gem- Received 11th December 2020 dibromoalkenes with arylsulfonyl methyl isocyanides was described for the synthesis of 3-aryl-2,4- Accepted 16th March 2021 disulfonyl-1H-pyrroles. The main highlight of this study is the introduction of a new dual-functional DOI: 10.1039/d0ra10451e reactivity of arylsulfonyl methyl isocyanides as the sulfonyl source as well as a 1,3-dipolar reagent in the rsc.li/rsc-advances same reaction. This system is facilitated by Cs2CO3 mediation in DMSO and 100 C conditions. Creative Commons Attribution 3.0 Unported Licence. Introduction features of less sterically congested a-C–H bonds and enhanced electrophilicity as a consequence of additional sulfonyl func- Since its rst isolation from bone pyrolysis in 1857, the pyrrole tionality distinguish this reactive reagent from other alkyl iso- 12,13 unit was identied as a fundamental substructure of numerous cyanides (Fig. 1). important natural and bioactive unnatural products.1 Lamel- Moreover, sulfonyl function as a leaving group can offer larin R as an anti-cancer and anti-HIV alkaloid,2 and other active TosMIC an efficient source of sulfonyl group, whereby it can act 12 pyrrolizidine alkaloids, chlorophyll, cobalamin (vitamin B12), as a dual reagent and/or as a sulfonylation reagent.
    [Show full text]
  • Development of a Pet Probe for the Imaging of Cox-2 Expression in Cancers
    THE UNIVERSITY OF HULL DEVELOPMENT OF A PET PROBE FOR THE IMAGING OF COX-2 EXPRESSION IN CANCERS being a Thesis submitted for the degree of Doctor of Philosophy in the University of Hull by Anna Pacelli MSc (Università degli Studi di Bari “Aldo Moro”) May 2015 Considerate la vostra semenza: fatti non foste a viver come bruti, ma per seguir virtute e canoscenza” Dante Alighieri, Inferno, Canto XXVI List of contents Abstract 1 List of Abbreviations 2 List of Figures 5 List of Schemes 8 List of Tables 10 Acknowledgements 11 1. Cyclooxygenase 13 1.1 Eicosanoids 15 1.1.1 Biosynthesis of eicosanoids 15 1.1.2 Eicosanoids and inflammation 17 1.1.3 Eicosanoids and cancer 19 1.2 Involvement of COX-2 in cancers 20 1.2.1 Colorectal cancer 21 1.2.2 Oesophageal cancer 22 1.2.3 Gastric cancer 23 1.2.4 Breast cancer 24 1.2.5 Brain cancer 24 1.2.6 Lung cancer 25 1.2.7 Chemoresistance 26 1.2.8 COX-2 as a biomarker for stratification of cancer patients 27 1.3 COX inhibitors: NSAIDs 27 1.3.1 Structure-Activity Relationship studies 27 1.3.2 Kinetics of COX inhibition 31 1.3.3 COX inhibition assays 33 2. Molecular imaging 36 2.1 Fluorescence imaging (FI) 37 2.2 Single Photon Emission Computed Tomography (SPECT) 38 3. Positron Emission Tomography 39 3.1 Principles of PET 39 3.2 Development of a PET probe 41 3.3 Oncological PET imaging 46 3.3.1 Applications of PET imaging 47 3.3.2 Imaging of COX-2 expression 50 3.3.2.1 Carbon-11 radiolabelling 41 3.3.2.2 Fluorine-18 radiolabelling 52 3.3.2.3 Iodine-123 and Iodine-125 radiolabelling 54 3.4 Fluorine-18 Radiochemistry 57 3.4.1 Fluorine-18 radiolabelling via nucleophilic substitution 58 3.4.2 Fluorine-18 radiolabelling via electrophilic substitution 59 3.4.3 Novel approaches to fluorine-18 radiolabelling 60 4.
    [Show full text]
  • Cycloaddition of Tosylmethyl Isocyanide with Styrylisoxazoles
    molecules Article [3+2] Cycloaddition Cycloaddition of of Tosylmethyl Tosylmethyl Isocyanide withwith Styrylisoxazoles: Facile Facile Access to Polysubstituted 3- (Isoxazol-5-yl)pyrroles3-(Isoxazol-5-yl)pyrroles Xueming Zhang 1,, Xianxiu Xianxiu Xu Xu 22 andand Dawei Dawei Zhang Zhang 1,1,** 1 1 CollegeCollege of of Chemistry, Chemistry, Jilin Jilin University University,, Changchun Changchun 130012, 130012, China; China; [email protected] [email protected] 2 2 CollegeCollege of of Chemistry, Chemistry, Chemical Chemical Engineering Engineering and and Materials Materials Science, Science, Key Key Laboratory Laboratory of of Molecular Molecular and and NanoNano Probes, Probes, Ministry Ministry of of Education, Education, Shan Shandongdong Normal Normal University, University, Jinan Jinan 250014, 250014, China; China; [email protected]@sdnu.edu.cn * Correspondence:Correspondence: [email protected]; [email protected]; Tel.: Tel.: +86-431-878-36471 +86-431-878-36471 Received: 16 June 2017; Accepted: 3 3 July July 2017; Published: 7 7 July July 2017 2017 Abstract: A facile access to polysubstitutedpolysubstituted 3-(isoxazol-5-yl)pyrroles3-(isoxazol-5-yl)pyrroles was developed through [3+2] cycloaddition of of tosylmethyl isocyanide isocyanide (TosMIC) (TosMIC) and styrylisoxazoles. In In the the presence presence of of KOH, KOH, various styrylisoxazolesstyrylisoxazoles reactedreacted smoothly smoothly with with tosylmethyl tosylmethyl isocyanide isocyanide and and analogs analogs to deliver to deliver a wide a widerange range of 3-(isoxazol-5-yl)pyrroles of 3-(isoxazol-5-yl)pyrroles at ambient at ambient temperature. temperature. This This transformation transformation isis operationally simple, high-yielding, and displays broad substrate scope. Keywords: isoxazol-5-ylpyrroles;isoxazol-5-ylpyrroles; [3+2]cycloaddition; TosMIC; TosMIC; 3-methyl-4-nitro-5-styrylisoxazoles 1.
    [Show full text]
  • Tosmic: Apowerful Synthon for Cyclization and Sulfonylation Kapil Kumar[A]
    REPRINT Reviews ChemistrySelect doi.org/10.1002/slct.202001344 z Organic &Supramolecular Chemistry TosMIC: APowerful Synthon for Cyclization and Sulfonylation Kapil Kumar[a] p-tosylmethyl isocyanide (TosMIC) which is also known as van focused on synthetic utility of TosMIC in diverse range of Leusen’s reagent hold the three functionalized groups includ- heterocycles like five membered heterocycles, fused hetero- ing the isocyanide and sulfonyl group and an alpha carbon cycles, linked or tethered heterocycles, spiro compounds etc. It which is acidic by nature. Tosyl set of this fortunate reagent is also utilized for regio, chemo and stereoselective synthesis acts as agood leaving group and assist the alpha carbon to and production of sulfones and sulfinates. It serves as an contribute in arange of cyclization strategies. Exceptionally, important building block in various synthetic methodologies TosMIC was also proved as agood sulfonylating and sulfometh- like multi component reaction, cyclization, domino, cascade ylating reagent. TosMIC has proved as apowerful and versatile and cycloaddition and metal catalysedreactions. Various new synthon and betrothed in the synthesis of broad range of catalyst and novel methodologies were explored due to heterocycles having pharmacological interest. This review is enormous use of this wonderful reagent. 1. Introduction Isocyanide has been crowned as imaginative reagent by medicinal chemist due to their synthetic utility and pharmaco- logical applications.Abroad range of isocyanides are reported in literature but p-tosylmethyl isocyanide attracted the syn- thetic chemists because of its applicability in diversified reaction categories. p-toluenesulfonylmethyl isocyanide, gener- ally abbreviated as TosMIC, has drawn attention of researchers due to its astonishing structural features, constancy and reactivity.
    [Show full text]
  • Tosmic Whitepaper
    Benefits of Using TosMIC in Various Applications Abstract With three important chemical groups—specifically, an isocyanide, a tosyl and an acidic α-carbon in-between—contained within its structure, TosMIC (CAS# 36635-61-7) is a versatile synthetic reagent and building block in organic synthesis. This technical whitepaper highlights three mission-critical industrial applications, namely TosMIC’s roles in converting carbonyl groups to nitriles as a cyanating reagent; synthesizing heterocyclic compounds such as oxazoles, imidazoles and pyrroles; and preparing Knoevenagel-type condensation products. Background Tosylmethyl isocyanidei, or TosMIC, is a colorless solid that can be stored at room temperature without decomposing. Unlike other isocyanides however, TosMIC is effectively odorless1. It has a melting point of 111–113 °C, and is insoluble in water but soluble in organic solvents such as dimethoxyethane (DME) and tetrahydrofuran (THF)2,3. Structurally, as may be seen in Figure 1, TosMIC’s versatility stems from three key components: the isocyanide (blue) and tosyl (pink) groups, and the acidic α-carbon (red). The isocyanide, which undergoes addition-type reactions, has a carbon atom that usually acts as an electrophilic center for ring-closing reactions (and may double as an active methylene group for secondary reactions)1,4,5. This carbon atom also typically exhibits carbene-like reactivity, which is reflected in the first resonance structure and its canonical hybrid on the right6. Regarding the tosyl, it acts as a good leaving group in the generation of heterocycles4. Finally, the α-position’s reactivity stems from the strong electron- withdrawing effects of the other two groups (though the α-position is also less sterically hindered)1,7.
    [Show full text]
  • SYNTHESES USING ISONITRILES a Thesis Presented by DIONYSIOS PAPAIOANNOU in Partial Fulfilment of the Requirements for the Award
    SYNTHESES USING ISONITRILES A Thesis presented by DIONYSIOS PAPAIOANNOU in partial fulfilment of the requirements for the award of the degree of DOCTOR OF PHILOSOPHY OF THE UNIVERSITY OF LONDON Hofmann Laboratory Chemistry Department DECEMER 1977 Imperial College London S17 2AY To my Parents and Grandmother 2rovS Tovets kat ytayta you 3 ACKNOWLEDGEMENTS I wish to thank : Professor Sir Derek Barton, FRS, for all the encouragement and assistance he has given me, and for • his patient and perceptive guidance of this project. Dr. A. G. M. Barrett for cosupervising this project, for reading the manuscript and giving valuable suggestions. Dr D. A. Widdowson for cosupervising part of this work. Dr. S. Singh for helpful discussions and Dr. R. W. Read for useful suggestions and for reading this Thesis. All my friends and colleagues in the Hofmann Laboratory,_ past and present, whose advice, assistance and good-fellowship were of great value. The staff of the Chemistry Department for their essential analytical, spectral and technical services. Dionysios Papaioannou • ABSTRACT The reactions of isonitriles with carbonyl compounds or their derivatives under basic and acidic conditions and the chemistry of toluene-4-sulphonylmethyl isocyanide (TosMIC) are reviewed. Recent developments in phenol oxidative coupling are also summa.rised. Novel oxidants, including vanadium oxyhalides and thallium(III) trifluoro- acetate, and electroorganic coupling are described in full. Isonitriles have been studied and shown to be useful intermediates in the synthesis of 1-benzylisoquinolines. A novel approach to these alkaloids,. based on TosMIC as a C-N-C synthon and the available aromatic aldehyde C6-C1 units, was explored.
    [Show full text]